MarketCapExport financials
Medpace Holdings (MEDP)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Medpace Holdings Balance Sheet 2025-2011 | MEDP
Brief balance sheet overview of Medpace Holdings
Balance sheet changes are traced across five available annual reports between 2021 and 2025.
The balance sheet expanded from $1.7 billion to $2 billion. Growth of +19% and CAGR of 4.4% look measured and sustainable.
Liabilities expanded faster than the asset base, +114.5% versus +19%. Debt-service capacity deserves attention.
Equity funds just 23.2% of assets versus 57.4% previously. The balance sheet is sensitive to weaker results.
The period ended with net cash: net debt stood at -$360.2 million. This supports financial flexibility.
Cash represents 25.2% of assets versus 27.8% initially, showing how the immediate liquidity reserve changed.
Retained earnings are negative at -$460 million. This reduces the formal capital cushion, although large shareholder returns may have contributed.
What the balance sheet shows
Medpace Holdings's balance sheet looks stretched: reliance on liabilities and a limited capital cushion increase sensitivity to weaker results.
Annual Balance Sheet Medpace Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-360 M | -520 M | -81 M | 130 M | -314 M | - | -86.7 M | 56.4 M | 195 M | 127 M | 363 M | 437 M | - | - | - |
Long Term Debt |
114 M | 126 M | 142 M | 139 M | 131 M | - | - | 79.7 M | 205 M | 151 M | 378 M | 492 M | - | - | - |
Long Term Debt Current |
23.2 M | 23.3 M | 22.4 M | 19.3 M | 16.3 M | 15.9 M | 11 M | - | 16.5 M | 12.4 M | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | 73.8 M | 121 M | 254 M | 200 M | 437 M | 561 M | - | - | - |
Total Current Liabilities |
1.34 B | 1.1 B | 925 M | 803 M | 557 M | 440 M | 343 M | 257 M | 193 M | 169 M | - | - | - | - | - |
Total Liabilities |
1.52 B | 1.28 B | 1.1 B | 966 M | 707 M | 585 M | 417 M | 378 M | 447 M | 368 M | 571 M | 695 M | - | - | - |
Deferred Revenue |
854 M | 711 M | 560 M | 463 M | 345 M | 256 M | 192 M | 148 M | 73.8 M | 65.7 M | 51.1 M | 58.1 M | - | - | - |
Retained Earnings |
-460 M | 8.17 M | -222 M | -360 M | 235 M | 115 M | 68.1 M | -41.5 M | -120 M | -9.58 M | -23 M | -14.3 M | - | - | - |
Total Assets |
1.98 B | 2.1 B | 1.66 B | 1.35 B | 1.66 B | 1.39 B | 1.14 B | 968 M | 951 M | 979 M | 984 M | 1.1 B | - | - | - |
Cash and Cash Equivalents |
497 M | 669 M | 245 M | 28.3 M | 461 M | 278 M | 132 M | 23.3 M | 26.5 M | 37.1 M | 17.7 M | - | - | - | - |
Book Value |
459 M | 826 M | 559 M | 386 M | 953 M | 806 M | 726 M | 590 M | 504 M | 611 M | 413 M | 402 M | - | - | - |
Total Shareholders Equity |
459 M | 826 M | 559 M | 386 M | 953 M | 806 M | 726 M | 599 M | 504 M | 611 M | 413 M | 402 M | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Medpace Holdings
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
114 M | 120 M | 122 M | 114 M | 119 M | 125 M | 127 M | 126 M | 128 M | 132 M | 136 M | 142 M | 143 M | 139 M | 143 M | 139 M | 139 M | - | 142 M | 131 M | 128 M | 113 M | 114 M | 115 M | 115 M | 115 M | 115 M | - | - | - | 55.8 M | 79.7 M | 79.7 M | 79.7 M | 79.7 M | 205 M | 205 M | 205 M | 205 M | 151 M | 151 M | 151 M | 151 M | 378 M | 378 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
1.52 B | 1.62 B | 1.53 B | 1.52 B | 1.46 B | 1.4 B | 1.3 B | 1.28 B | 1.2 B | 1.16 B | 1.12 B | 1.1 B | 1.02 B | 1.02 B | 1.05 B | 966 M | 979 M | - | 739 M | 707 M | 679 M | 618 M | 592 M | 585 M | 585 M | 585 M | 585 M | 417 M | 417 M | 417 M | 417 M | 378 M | 378 M | 378 M | 378 M | 447 M | 447 M | 447 M | 447 M | 368 M | 368 M | 368 M | 368 M | 571 M | 571 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
854 M | 905 M | 856 M | 854 M | 834 M | 809 M | 719 M | 711 M | 671 M | 638 M | 617 M | 560 M | 519 M | 491 M | 466 M | 463 M | 418 M | - | 367 M | 345 M | 304 M | 282 M | 278 M | 256 M | 256 M | 256 M | 256 M | 192 M | 192 M | 192 M | 192 M | 148 M | 148 M | 148 M | 126 M | 73.8 M | 68.3 M | 65.6 M | 60.5 M | 65.7 M | 65.7 M | 65.7 M | 65.7 M | 51.1 M | 51.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-460 M | -511 M | -336 M | -460 M | -596 M | -703 M | -270 M | 8.17 M | 65.6 M | -30.8 M | -119 M | -222 M | -300 M | -371 M | -408 M | -360 M | -380 M | - | -121 M | 235 M | 185 M | 142 M | 159 M | 115 M | 115 M | 115 M | 115 M | 68.1 M | 68.1 M | 68.1 M | 68.1 M | -41.5 M | -41.5 M | -41.5 M | -41.5 M | -120 M | -120 M | -120 M | -120 M | -9.58 M | -9.58 M | -9.58 M | -9.58 M | -23 M | -23 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
1.98 B | 2.06 B | 2.13 B | 1.98 B | 1.75 B | 1.57 B | 1.9 B | 2.1 B | 2.08 B | 1.92 B | 1.8 B | 1.66 B | 1.49 B | 1.41 B | 1.4 B | 1.35 B | 1.33 B | - | 1.34 B | 1.66 B | 1.58 B | 1.47 B | 1.45 B | 1.39 B | 1.39 B | 1.39 B | 1.39 B | 1.14 B | 1.14 B | 1.14 B | 1.14 B | 968 M | 968 M | 968 M | 968 M | 951 M | 951 M | 951 M | 951 M | 979 M | 979 M | 979 M | 979 M | 984 M | 984 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
669 M | 503 M | 653 M | 497 M | 285 M | 46.3 M | 441 M | 669 M | 657 M | 511 M | 407 M | 245 M | 95.2 M | 39.1 M | 46.9 M | 28.3 M | 31 M | 42.6 M | 82.8 M | 461 M | 398 M | 339 M | 333 M | 278 M | 278 M | 278 M | 278 M | 132 M | 132 M | 132 M | 132 M | 23.3 M | 23.3 M | 23.3 M | 23.3 M | 26.5 M | 26.5 M | 26.5 M | 26.5 M | 37.1 M | 37.1 M | 37.1 M | 37.1 M | 14.9 M | 14.9 M | - | - | 54.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
459 M | 434 M | 598 M | 459 M | 294 M | 172 M | 594 M | 826 M | 881 M | 764 M | 672 M | 559 M | 471 M | 391 M | 347 M | 386 M | 350 M | - | 605 M | 953 M | 898 M | 852 M | 859 M | 806 M | 806 M | 806 M | 806 M | 726 M | 726 M | 726 M | 726 M | 590 M | 590 M | 590 M | 590 M | 504 M | 504 M | 504 M | 504 M | 611 M | 611 M | 611 M | 611 M | 413 M | 413 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
826 M | 434 M | 598 M | 459 M | 294 M | 172 M | 594 M | 826 M | 881 M | 764 M | 672 M | 559 M | 471 M | 391 M | 347 M | 386 M | 350 M | 283 M | 605 M | 953 M | 898 M | 852 M | 859 M | 806 M | 806 M | 806 M | 806 M | 726 M | 726 M | 726 M | 726 M | 599 M | 590 M | 590 M | 590 M | 509 M | 504 M | 504 M | 504 M | 611 M | 611 M | 611 M | 611 M | 413 M | 413 M | - | - | 402 M | - | - | 414 M | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Medpace Holdings, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Diagnostics research
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Burning Rock Biotech Limited
BNR
|
$ 11.95 | 1.1 % | $ 126 M |  China |
 |
Renalytix AI plc
RNLX
|
- | 5.66 % | $ 22.7 M |  Britain |
 |
Bioventus
BVS
|
$ 14.71 | -1.67 % | $ 980 M |  USA |
 |
Psychemedics Corporation
PMD
|
- | -1.84 % | $ 15.3 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
$ 26.77 | -0.48 % | $ 25.4 B |  Niderland |
 |
Meridian Bioscience
VIVO
|
- | - | $ 1.49 B | USA |
 |
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | USA |
 |
T2 Biosystems
TTOO
|
- | -39.35 % | $ 313 K | USA |
 |
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | USA |
 |
Celcuity
CELC
|
$ 66.71 | 2.26 % | $ 3.12 B | USA |
 |
Akumin
AKU
|
- | -17.87 % | $ 25.9 M |  Canada |
 |
Co-Diagnostics
CODX
|
$ 0.56 | 3.12 % | $ 745 K | USA |
 |
Quest Diagnostics Incorporated
DGX
|
$ 241.85 | 0.02 % | $ 26.8 B | USA |
 |
Danaher Corporation
DHR
|
$ 232.05 | 0.7 % | $ 165 B | USA |
 |
DexCom
DXCM
|
$ 77.69 | -0.33 % | $ 30.3 B | USA |
 |
Castle Biosciences
CSTL
|
$ 33.16 | 0.24 % | $ 961 M | USA |
 |
Fulgent Genetics
FLGT
|
$ 20.41 | 1.54 % | $ 628 M | USA |
 |
Heska Corporation
HSKA
|
- | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | USA |
 |
Guardant Health
GH
|
$ 174.47 | 3.19 % | $ 21.9 B | USA |
 |
Quotient Limited
QTNT
|
- | -11.32 % | $ 1.1 M |  Schweiz |
 |
IDEXX Laboratories
IDXX
|
$ 568.76 | 1.5 % | $ 45.7 B | USA |
 |
Illumina
ILMN
|
$ 271.02 | 0.59 % | $ 42 B | USA |
 |
IQVIA Holdings
IQV
|
$ 275.32 | -1.44 % | $ 47.3 B | USA |
 |
Lantheus Holdings
LNTH
|
$ 100.0 | 0.2 % | $ 6.75 B | USA |
 |
CareDx, Inc
CDNA
|
$ 68.8 | -0.6 % | $ 3.67 B | USA |
 |
Mettler-Toledo International
MTD
|
$ 1 667.03 | -0.07 % | $ 34.4 B | Schweiz |
 |
ENDRA Life Sciences
NDRA
|
$ 4.86 | 1.25 % | $ 3.82 M | USA |
 |
Neogen Corporation
NEOG
|
$ 12.31 | 0.98 % | $ 2.68 B | USA |
 |
National Research Corporation
NRC
|
$ 22.33 | 1.82 % | $ 500 M | USA |
 |
Natera
NTRA
|
$ 403.93 | 0.27 % | $ 55.2 B | USA |
 |
OPKO Health
OPK
|
$ 1.66 | 1.53 % | $ 1.25 B | USA |
 |
Precipio
PRPO
|
$ 19.23 | -3.9 % | $ 30.9 M | USA |
 |
RadNet
RDNT
|
$ 70.49 | 0.21 % | $ 5.3 B | USA |
 |
ICON Public Limited Company
ICLR
|
$ 184.42 | -0.46 % | $ 14.5 B |  Irlanda |
 |
Senseonics Holdings
SENS
|
$ 7.6 | 1.2 % | $ 317 M | USA |
 |
Sotera Health Company
SHC
|
$ 18.3 | 1.08 % | $ 5.2 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
$ 328.29 | -0.24 % | $ 27.3 B | USA |
 |
Thermo Fisher Scientific
TMO
|
$ 680.21 | 0.92 % | $ 256 B | USA |
 |
NeoGenomics
NEO
|
$ 16.79 | 1.21 % | $ 2.15 B | USA |
 |
Trinity Biotech plc
TRIB
|
$ 7.3 | -0.06 % | $ 2.62 B | Irlanda |
 |
Twist Bioscience Corporation
TWST
|
$ 145.71 | 4.14 % | $ 8.71 B | USA |
 |
VolitionRx Limited
VNRX
|
$ 0.18 | 3.1 % | $ 22.6 M |  Singapore |
 |
QIAGEN N.V.
QGEN
|
$ 50.5 | 0.21 % | $ 11 B | Niderland |
 |
Waters Corporation
WAT
|
$ 455.26 | 0.41 % | $ 27.1 B | USA |
 |
Exagen
XGN
|
$ 7.47 | 2.75 % | $ 161 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
- | - | $ 562 M | Britain |
 |
Brainsway Ltd.
BWAY
|
$ 11.06 | -1.69 % | $ 376 M |  Israel |
 |
Fluidigm Corporation
FLDM
|
- | 1.08 % | $ 308 M | USA |